000			01967 a2200517 4500
005			20250518050713.0
264		0	_c20200831
008			202008s 0 0 eng d
022			_a2155-384X
024	7		_a10.14309/ctg.0000000000000058 _2doi
040			_aNLM _beng _cNLM
100	1		_aMacek Jilkova, Zuzana
245	0	0	_aImmunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment. _h[electronic resource]
260			_bClinical and translational gastroenterology _c07 2019
300			_ae00058 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntigens, CD _xdrug effects
650	0	4	_aCD4-Positive T-Lymphocytes _xdrug effects
650	0	4	_aCD8-Positive T-Lymphocytes _xdrug effects
650	0	4	_aCarcinoma, Hepatocellular _xdrug therapy
650	0	4	_aDisease Progression
650	0	4	_aFemale
650	0	4	_aHepatitis A Virus Cellular Receptor 2 _xdrug effects
650	0	4	_aHumans
650	0	4	_aImmunotherapy _xmethods
650	0	4	_aLiver Neoplasms _xpathology
650	0	4	_aMale
650	0	4	_aNeoplasm Staging _xmethods
650	0	4	_aPredictive Value of Tests
650	0	4	_aPrognosis
650	0	4	_aProgrammed Cell Death 1 Receptor _xantagonists & inhibitors
650	0	4	_aProtein Kinase Inhibitors _xtherapeutic use
650	0	4	_aSorafenib _xtherapeutic use
650	0	4	_aUp-Regulation
650	0	4	_aLymphocyte Activation Gene 3 Protein
700	1		_aAspord, Caroline
700	1		_aKurma, Keerthi
700	1		_aGranon, Anouck
700	1		_aSengel, Christian
700	1		_aSturm, Nathalie
700	1		_aMarche, Patrice N
700	1		_aDecaens, Thomas
773	0		_tClinical and translational gastroenterology _gvol. 10 _gno. 7 _gp. e00058
856	4	0	_uhttps://doi.org/10.14309/ctg.0000000000000058 _zAvailable from publisher's website
999			_c29890899 _d29890899